Dubois-Stringfellow Nathalie 4

What Happened
Nathalie Dubois-Stringfellow, SVP and Chief Development Officer of Sangamo Therapeutics (SGMO), had portions of vested restricted stock units (RSUs surrendered) to cover mandatory tax withholding. On Feb 24, 2026 she surrendered 2,063 shares (withholding price ~$0.4725) for ~$975, and on Feb 25, 2026 she surrendered 12,354 shares (withholding price $0.47) for ~$5,806 — a total of 14,417 shares and roughly $6,781. These are tax-withholding dispositions (transaction code F), not open-market discretionary sales.

Key Details

• Transaction dates and prices:
  • 2026-02-24: 2,063 shares withheld at $0.4725/share (~$975) (F)
  • 2026-02-25: 12,354 shares withheld at $0.47/share (~$5,806) (F)
• Total surrendered: 14,417 shares for approximately $6,781.
• Shares owned after transaction: Not specified in this Form 4.
• Filing: Form 4 filed 2026-02-26 (two days after the Feb 24 transaction), which is within the standard 2-business-day Form 4 deadline.
• Footnotes / notable items:
  • These dispositions were mandatory tax withholdings on RSU vesting and are reported as dispositions for SEC purposes, not open-market trades.
  • The filing indicates the vested RSUs included shares from a Feb 24, 2023 RSU vesting installment and from a Feb 25, 2025 RSU grant (a one-quarter installment vesting on Feb 25, 2026, with remaining shares vesting in successive quarterly installments). Vesting is subject to continued service and potential acceleration per the issuer’s equity plan.

Context
This was a routine tax-withholding action tied to RSU vesting (transaction code F). Such withholdings are administrative dispositions and do not necessarily indicate the insider’s view on the company’s stock; purchases would generally be viewed as stronger signals of insider confidence.